RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF - sprookjes - yvandenbroek - TriplyDB

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

http://www.wikidata.org/entity/Q29616828

about

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions p21-Activated kinase 1 (Pak1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112 B-Raf and the inhibitors: from bench to bedside Melanoma: from melanocyte to genetic alterations and clinical options The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling Raf family kinases: old dogs have learned new tricks A secretory kinase complex regulates extracellular protein phosphorylation Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Complexity in KSR function revealed by Raf inhibitor and KSR structure studies Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Improved survival with vemurafenib in melanoma with BRAF V600E mutation Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment Genetics and biology of pancreatic ductal adenocarcinoma MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy MEK and PI3K inhibition in solid tumors: rationale and evidence to date Melanoma: oncogenic drivers and the immune system Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Targeting melanoma by small molecules: challenges ahead Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine Ten things you should know about protein kinases: IUPHAR Review 14 Functional genomics lead to new therapies in follicular lymphoma The dynamic nature of the kinome PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms Pathways and therapeutic targets in melanoma Tumour heterogeneity and the evolution of polyclonal drug resistance Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?Multiscale models of cell signaling.

P2860

Q21004109-F6F8A792-0D7C-4318-AA68-2BF14A8E4457 Q21134956-92C476E3-EB26-4DAD-85E1-0C82AFB44D63 Q21198860-5B723CA6-D2F3-4B2D-9801-E43F5EDBFE83 Q21284811-D46DF160-7FA2-4A6E-B565-5DE50BC2D9F1 Q21629049-E8E24281-E992-438F-BC9B-98DE0854A90C Q24294914-7EBDBF44-B4DF-46A8-A001-F0EA2BACCBCF Q24299821-6A7CCEEA-BB97-410A-A788-FFE164C6B4A7 Q24303940-AD21EBAD-BE1B-49CC-8D7A-37271B3FEE84 Q24314807-ADAEE1C1-81C3-4AE2-98F2-D86FB401DE56 Q24316181-97C7427D-0323-478F-99D0-8EBC00B50854 Q24323147-7D7CED62-2E6E-45BC-885D-60E0954D713C Q24594790-2DCC7801-A382-473A-AD6E-657CC96BAB8F Q24597152-6E926053-8C76-416D-A116-715BE242DEA5 Q24603489-18B5A349-32B8-474C-8412-AFCA491F91C0 Q24615826-C27D608B-8F52-48D3-9E54-4776FF79D046 Q24629474-E2FF1040-699C-4B6F-A019-43FAC947AF4E Q24631953-729053E6-0BA9-40F3-BF64-A26C3BD0AE28 Q24632064-7B7AF3E4-4CFB-4640-8B09-21D03CBCEAAF Q26744787-BCF869E7-F2E6-4EDF-9C10-DDFE7CFEA484 Q26751520-82D83ACA-EF1E-44CE-A8F2-BBADCDF10E23 Q26765438-77E15140-13CE-4F9D-90A8-0E98FD499BD1 Q26771192-0E974B48-B16B-4CF9-BF4D-D5944B621FAF Q26775573-83AC8B67-5468-4321-987B-4050EDDE0746 Q26775598-9D8ABE27-7FFB-4409-9ED6-5DC9DD11C58D Q26795510-CF570DC0-6FA1-4861-9438-5F0E57B33357 Q26795609-ED218E5F-CA0C-43A4-87EC-EE4ADF3F91F5 Q26795735-76CDE81F-C7BF-4A69-BD2D-E27CD0F8D08D Q26799864-0B0B3472-C5C2-4793-B284-0AA82AAC2DD9 Q26823978-5BC1780B-7132-45FF-AFD8-F457CA83F4B9 Q26824310-12DFEF05-2066-49E5-A58C-1CFA4FE80B18 Q26824642-9EF66487-20F8-431D-A98D-BEF34B057B24 Q26825186-7623078B-72E0-47F1-A33A-2B757DAC759F Q26849417-495F1879-A314-4E8E-8565-B44E327BF48C Q26852415-BE567D7A-001A-4C34-8196-A18C3816D3A5 Q26852588-2F12DFD1-E603-4306-9A2E-2E21BF9316F6 Q26862544-7CD5B534-0206-4433-AC1C-2438588395A8 Q26865736-8E3D2250-4D2E-40D5-9A77-748118173F31 Q26866803-534630D0-BE97-424D-B939-6647BEB22A2C Q27001584-89B6393F-010D-4521-916B-95557E1765EC Q27010700-B175BFA4-D6C5-4B26-9D4E-72BF425115FA

P2860

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

http://www.wikidata.org/entity/Q29616828

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

@ast

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

@en

type

label

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

@ast

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

@en

prefLabel

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

@ast

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

@en

P1433

Q29616828-15496FC6-DFFF-4E35-90E8-DD0FE36749FC

P1476

Q29616828-30637918-F24C-46D6-9B97-E7B9FAEAF15E

P2093

Q29616828-3487ECD5-628B-43AE-95E6-803330B79C10

Q29616828-376E350F-686C-414A-BACB-2F43F4E66402

Q29616828-40AFA27A-E728-4D5B-BD69-264092BDB914

Q29616828-7EDB9DAC-123A-4C98-AA90-5D68CF5442CD

Q29616828-8A512E00-D17C-42E3-BAF3-B32FB0AEB714

P2860

Q29616828-0964CB74-2B02-4A6C-B7D3-EB69AAA22C30

Q29616828-0FBB6CDF-6C54-4035-8898-209CB82B10B7

Q29616828-16733CD6-53CD-476B-B8D4-A877FC312B08

Q29616828-1AB3E083-937D-47E5-9B72-87465914F86B

Q29616828-1AC9B0B9-8855-478A-8A5A-97E277DE8C98

Q29616828-287B20B8-8EAF-4CEE-A5C4-FCE9501CE2BB

Q29616828-3327DE27-CF1B-4D25-B5C8-0353B3B3E74F

Q29616828-3960189A-905A-4049-AE42-5956BEBAA2A0

Q29616828-4C977A85-6C1A-42D8-ADFC-FA6ED37B8B29

Q29616828-509D7BFB-2181-4B63-87B2-2EC2E7B557DF

P2888

Q29616828-40C16646-9DA2-43F9-8EFD-F794E5853549

P304

Q29616828-057A38A3-356C-4B78-A504-1981C98B4B1F

P31

Q29616828-A1D8BCCE-0474-424E-BED8-9FF3ED8FF9D9

P3181

Q29616828-5DBE06B9-5E87-480C-96A5-88C25E413594

P356

Q29616828-806FE67B-9754-4A05-B3EB-B98774D5579E

P407

Q29616828-262CB274-3B91-48D9-ADB7-14D8FB32A9E1

P433

Q29616828-35D2021D-499E-4D58-B9F7-FE2675CEE7E3

P478

Q29616828-6AB56F5F-B564-4B54-8841-6E051D12E0D4

P577

Q29616828-AE537F21-20E7-4D0D-8A23-3C5EF96DFB22

P5875

Q29616828-CB929230-2731-4F7A-9D60-8F69AFE2188A

P6179

Q29616828-D760BAB8-203E-474E-8AB3-FBB67465EDA0

P698

Q29616828-B33A2A6F-565C-46C4-8E34-4E69A24106CD

P932

Q29616828-B3567DD5-BC80-492F-8240-17B6BEF1349F

P3181

P356

P1433

P1476

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

@en

P2093

Bollag G

http://www.w3.org/2001/XMLSchema#string

Poulikakos PI

http://www.w3.org/2001/XMLSchema#string

Rosen N

http://www.w3.org/2001/XMLSchema#string

Shokat KM

http://www.w3.org/2001/XMLSchema#string

Zhang C

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Autoregulation of the Raf-1 serine/threonine kinase

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

A dimerization-dependent mechanism drives RAF catalytic activation.

Active Ras induces heterodimerization of cRaf and BRaf

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Regulation and role of Raf-1/B-Raf heterodimerization.

BRAF mutation predicts sensitivity to MEK inhibition

P2888

P304

427-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

867340

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE08902

http://www.w3.org/2001/XMLSchema#string

P407

P433

7287

http://www.w3.org/2001/XMLSchema#string

P478

464

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41548756

http://www.w3.org/2001/XMLSchema#string

P6179

1006916541

http://www.w3.org/2001/XMLSchema#string

P698

20179705

http://www.w3.org/2001/XMLSchema#string

P932

3178447

http://www.w3.org/2001/XMLSchema#string